Aim: The aims of this study were to assess survival outcome of pediatric patients with localized osteosarcoma of the extremities in Upper Egypt, identify factors of prognostic significance for survival, and to determine factors predictive of surgical methods used in these patients, as well as developing a clinical model for risk prediction.
O steosarcoma is the most common of all primary malignant bone tumors. [1] [2] [3] [4] [5] [6] Accounting for about 2.6% of all pediatric neoplasms, 7 it predominantly occurs in the extremities, 5, 8 with a peak incidence in the second decade of life. [9] [10] [11] The advent of incorporation of systemic chemotherapy along with surgery in the treatment of osteosarcoma in the 1960s [12] [13] [14] [15] has been followed by an increased use of multiagent chemotherapy regimens in the 1970s and 1980s. [16] [17] [18] [19] [20] By the time, the integration of highly effective regimens, which included cisplatin, adriamycin, high-dose methotrexate, and ifosfamide, with more treatment refinement according to disease risk, has led to the improvement of survival in localized osteosarcoma of the extremities to approach 80%. [21] [22] [23] [24] [25] Albeit survival outcomes thereafter reached a plateau, by the 1990s and with the advancement of surgical techniques, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] a major shift of the methods used for the surgical resection of osteosarcoma from the limb amputation 36, 37 to limb salvage has occurred with a success rate that may exceed 90% in the most specialized sarcoma centers. 26, [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] In contrast, the outcomes for nonmetastatic osteosarcoma in countries with limited resources have been less satisfactory, particularly with regard to the rate of limb salvage surgery. [46] [47] [48] In Upper Egypt, we have a higher proportion of the population in underdeveloped communities with a limited access to medical care; hence, these patients usually seek medical advice at an advanced stage, with a higher prevalence of metastatic disease at initial presentation, as well as with larger tumor size 46, 49, 50 that has more likelihood of potential adverse risk criteria before surgery.
A previous study from Upper Egypt showed that a metastatic disease at diagnosis was independently correlated to a dismal outcome. 46 As the effect of many other factors of prognostic significance, such as, sex, age, tumor location, and response to chemotherapy, may have been mitigated by the large effect of the metastatic disease on the prognosis, we will therefore analyze the data of 30 patients with nonmetastatic osteosarcoma of the extremities, to determine prognostic factors associated with their survival, as well as to develop a model, based on baseline clinical data and the tumor response to chemotherapy, for better prediction of the factors correlated with a certain surgical approach that has been used in these patients.
PATIENTS AND METHODS

Study Patients
The assembled data from the medical records of 30 patients in whom the diagnosis of nonmetastatic osteosarcoma of the extremities was verified, and who were treated between 2001 and 2015 in the pediatric oncology department, South Egypt Cancer Institute, were processed for further analysis. The flow diagram of the study participants was shown in the Supplementary Data File (Supplemental Digital Content 1, http://links.lww.com/JPHO/A308).
The collected data were related to age; sex; treatment period; anatomic location within the limb, that is, proximal versus distal (proximal, defined as above the elbow or the knee; distal, below the elbow or the knee); location within the bone, that is, upper versus lower (upper, within the upper bone metaphysis; lower, within the lower bone metaphysis); the type of definitive surgery, that is, limb salvage versus amputation; the surgical resection margin, that is, positive versus negative; the tumor response to chemotherapy, that is, good versus poor; the type of recurrence, that is, local, systemic, or combined; and time to event or death; these data were used to form the variables utilized in the final statistical analysis.
Diagnosis and Staging
Histopathologic diagnoses were made for all the patients from the tissue specimens obtained by an open incisional biopsy performed by the orthopedic surgeon, taking into consideration that the biopsy track sites would be removed en bloc along with the tumor at the time of definitive surgery. All the patients included in the study were classified as "IIB," that is, (G2-high grade, T2-extracompartmental, M0-no metastasis) according to the Enneking surgical staging system (also known as the MSTS system) adopted by the Musculoskeletal Tumor Society.
Clinical Management and Treatment Strategies
Taking into consideration the skeletal maturity; technical availability of reconstruction flaps, grafts, or prostheses; and patient preferences, surgery was scheduled for all patients at 3 weeks after completing 3 cycles of neoadjuvant chemotherapy protocol comprised of doxorubicin 75 mg/m , with every attempt to obtain an adequate resection margin. Every attempt has been made to save the limb unless the patient's life would likely to be compromised with potentially contaminated margins or that the limb function would be jeopardized with extensive resection. Limb amputation was a safe alternative. All the patients have been scheduled for 3 postoperative cycles of the same protocol, regardless of the histologic response to preoperative chemotherapy.
Statistical Analysis
Continuous variables were expressed as mean ( ± SD) or median (range or interquartile range). Categorical variables were presented as proportions or percentages. The χ 2 was used to test differences between groups for categorical variables, or the Fisher exact test, when appropriate. We applied time-to-event methodology to measure survival probabilities using the Kaplan-Meier analysis, and differences among groups were compared using the log-rank test. In the survival analysis, time to systemic recurrence and time to death were selected as the primary endpoints.
Patients were censored at the date of the last follow-up if an event or death did not occur. The follow-up period end was set at December 31, 2017.
Cox proportional hazard regression analysis, "hazard ratios" (HRs), was used to evaluate effects of various study variables on survival outcomes, whereas binary logistic regression analysis, 'odds ratios" (ORs), was utilized to assess the likelihood of association of the study variables with the study outcomes, that is, response to chemotherapy, the surgical method used, or occurrence of systemic recurrence. The assumptions for proportionality of hazards were satisfied.
For the purpose of the study, due to the small sample size, and to maintain a ratio of 5 to 9 events per predictor, 51 which is the minimal acceptable ratio for a specific parameter to be included in a model, and in an attempt to reduce the number of predictors in the final multivariable regression model, we saved the probabilities of the baseline potential confounders in "1 covariate" to statistically hold constant their effects while looking at the desired outcome "covariate adjustment using the propensity score." [52] [53] [54] [55] [56] Using "the receiver operating characteristic" (ROC) curve, an optimal cutoff point for splitting the age as a continuous variable into a dichotomous variable, age below 16 years and 16 years or above, was chosen to maximize both sensitivity and specificity for the purpose of discriminatory classification according to the patient survival outcomes 57 (Fig. 1A) . We also made use of the ROC curve to further evaluate a certain model for its utility by assessing sensitivity, specificity, and the area under the curve. 58 To guard against overfitted and optimistic models, particularly when sample size is small, "forced entry" or "all-variables-together" method was used for selection of predictors in the multivariable modelling procedure; however, backward elimination [59] [60] [61] [62] was used to eliminate a certain predictor from a set of highly correlated predictors such age as a continuous variable and the age as a dichotomous variable. We used the test of "the likelihood ratio" to select the most parsimonious model with the best fit, 63 or, when appropriate, the "Akaike Information Criterion," which accounts for model fit while penalizing for the number of parameters being estimated, and corresponds to using P-value = 0.157, or the "Bayesian Information Criterion," reported to be particularly useful with a small sample size. 64 Bootstrapping using the original study sample was used as a technique for internal validation, while temporal splitting of the sample into different treatment periods was carried out, as was reported as an acceptable, however, a suboptimal form of external model validation, or as an intermediate between internal and external validation. 59, 62, 65 Further external validation necessitates comparison with another future study sample. All statistical tests were described with 95% confidence interval (CI), and an arbitrary P-value was set at 0.05. All P-values were 2 tailed. Statistical analyses were performed using SPSS, version 20.0, for Windows (SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
Of 30 patients with localized osteosarcoma, 56.7% (17/ 30) of the study population were female individuals, 66.7% (20/30) were under 16 years, 50% (15/30) were treated in the period spanning from 2011 to 2015, and 40% (12/30) were located in a distal extremity. Patient characteristics according to the tumor response to chemotherapy are shown in Table 1 .
Survival Outcomes
With a median follow-up period of 63 months (95CI% 56.8-69.2, SEM = 3.17) for the study patients, the estimates for event-free survival (EFS) and overall survival (OS) at 3 and 5 years were 69.5% and 79%, and 65.2% and 65.3%, respectively (Fig. 2) .
Of 30 patients, 20 remained continuously disease free, and of the 10 patients who experienced events, isolated distant recurrence occurred in 8 patients, combined distant and local recurrence occurred in 1 patient, whereas 1 patient relapsed locally. The median time to recurrence was 25 months (range: 15-49 mo), and median postrecurrence survival time was 8 months (range: 5-38 mo). Nine patients died; all of them succumbed to their disease due to uncontrolled, progressive disease, whereas 1 patient was alive with disease at the time of analysis.
Analyses of Prognostic Factors
Metastasis-Free Survival
Age 16 years or above was associated with worse metastasis-free survival (MFS) both in the univariable (HR = 5.14, 95% CI: 1.28-20.6, P = 0.021) and multivariable analysis (HR = 6.05, 95% CI: 1.43-25.6, P = 0.015). Poor response to chemotherapy was found to be significantly associated with MFS (HR = 4.92, 95% CI: 1.02-23.8, P = 0.047) only in the univariable analysis. Predictors of MFS in the univariable and multivariable analysis are shown in Table 2 .
Overall Survival
Age 16 years or above was associated with worse OS both in the univariable (HR = 5.6, 95% CI: 1.4-22.7, P = 0.015) and multivariable analysis (HR = 7.9, 95% CI: 1.71-36.2, P = 0.008). A proximal location within the limb and a poor response to chemotherapy showed nonsignificant trend toward worse OS in the univariable analysis; however, a proximal location (HR = 2.4, 95% CI: 1.13-22.1, P = 0.003) gained a statistical significance in the multivariable analysis. Predictors of OS in the univariable and multivariable analysis are shown in Table 3 . OS curves at 5 years, according to sex and response to chemotherapy, are shown in Fig. 3A .
Systemic Recurrence
Systemic recurrences developed in 9/30 (30%) patients after a median time of 24 months (15 to 49 mo). Systemic recurrence occurred in 2/16 (12.5%) of good responders versus 7/14 (50.0%) of poor responders (P = 0.046), and it occurred in 4/17 (23.5%) after limb salvage versus 5/13 (38.5%) in amputated patients (P = 0.44). MFS at 5 years was 60.6% after amputation surgery versus 76% after limb salvage surgery (P = 0.55), and it was 87.5% in good responders versus 45.4% in poor responders (P = 0.027). MFS curves at 5 years, according to response to chemotherapy and the type of surgery, are shown in Fig. 3B .
Age 16 years or above (OR = 20.3, 95% CI: 1.24-334.3, P = 0.035) retained its statistical significance as an independent predictor for the occurrence of systemic recurrence in the multivariable analysis (Table 4) .
Using logistic regression analysis, a model developed to predict systemic recurrence as a whole explained between about 41.8% (Cox and Snell R 2 ) and 59.2% (Nagelkerke R 2 ) of the variance due to the explanatory variables; P-value of Hosmer and Lemeshow goodness-of-fit test of this model was 0.57. The classification table built to evaluate predictive accuracy of the model has correctly classified 83.3% of cases. Further evaluation of the model using the ROC showed an area under the curve of 0.93 (95% CI: 0.84-1.00, P < 0.001) (Fig. 1B) .
Local Recurrence
The overall local recurrence rate in our study was 6.7% (2/30): 11.8% (2/17) for those who underwent limb salvage surgery, and no recurrences (0/13) for those who underwent limb 
Histologic Response to Chemotherapy
After definitive surgery, 53.3% (16/30) of patients was shown to have a good response to chemotherapy. In the univariable analysis, poor response to chemotherapy was shown to be associated with worse EFS (HR = 5.67, 95% CI:
1.2-26.8, P = 0.029), marginally correlated to both inferior MFS (HR = 4.92, 95% CI: 1.02-23.8, P = 0.047), and OS (HR = 4.37, 95% CI: 0.91-21.0, P = 0.066). In the multivariable analysis, a statistically significant association between the tumor response to chemotherapy and survival was lost. Factors predictive of tumor response to chemotherapy are shown in Table 5 . The ROC curve was used to further evaluate the predictive accuracy of response to chemotherapy using patient baseline clinical data (Fig. 1C) .
Type of Definitive Surgical Procedure
Limb salvage surgery was performed in 56.7% (17/30) of patients. In the univariable analysis, age 16 years or above (OR = 5.44, 95% CI: 1.04-28.5, P = 0.045) and a tumor that was poorly responding to chemotherapy (OR = 5.40, 95% CI: 1.12-26.0, P = 0.036) were associated with more likelihood of an amputation surgery. In the multivariable analysis, the patients found to be more likely to undergo an amputation surgery (OR = 14.1, 95% CI: 1.34-149.4, P = 0.028) were those in whom a tumor was poorly responding to chemotherapy. The predicted probabilities from the 3 confounders were saved and used as a single covariate in the multivariable regression model to control for potential baseline confounders of the effect of "tumor response to chemotherapy" on "type of surgical procedure" used in these patients. Factors predictive of the surgical method using propensity score adjustment for confounders are shown in Table 6 . The model was internally validated after splitting the sample into 2 groups according to the treatment period using the classification table of logistic regression analysis. Each of the 2 subsamples yielded a classification table with a comparable ability of predictive accuracy to correctly classify cases in both groups. The ROC curve was used to further evaluate the utility of the model. Using a cutpoint with a predicted probability of 0.35 that a limb amputation surgery would be performed provided a sensitivity of 84.6% and a specificity of 70.6%, whereas a cutpoint of 0.74 corresponded to a sensitivity of 38.5% and a specificity of 88.2%. The area under the ROC curve was 0.83 (95% CI: 0.67-0.99, P = 0.002) (Fig. 1D) .
DISCUSSION
In the present study, the estimates for EFS and OS at 3 and 5 years for those patients with localized osteosarcoma were 69% and 79% and 65.2% and 65.3%, respectively, which were comparable to what was reported in other international studies. 22, 25, [66] [67] [68] [69] [70] [71] [72] However, we had a limb salvage rate of 56.7%, which was lower than figures reported from the recently published studies, despite still being comparable with the published results from a former treatment era, [26] [27] [28] 34, 43, 44, 68, [73] [74] [75] [76] [77] [78] [79] albeit still higher than some recent reports. 47, 76, 80 Many challenges related to limb salvage surgery include achieving adequate surgical margin without compromising the limb function after tumor removal, availability of the proper prosthesis and tissue grafts for adequate fixation, in addition to the presence of sufficient expertise to reconstruct the limb with minimal complications. 35, [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] These restrictions represent technical, logistical, and financial issues that are still limited in developing countries. 48, [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] Previous studies have shown conflicting results of the prognostic effect of age on survival. 66, 79, 80, [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] In our study, a clear tendency for decreased survival with increasing age was shown in both the univariable and multivariable analyses, as shown in a multi-institutional study from Japan. 21 This effect was more pronounced when the comparison was carried out after age classification into 2 subgroups according to the ROC curve. A lesser proportion of female individuals was observed in patients 16 years of age or above (4/10, 40%) compared with patients whose age was younger than 16 years ([13/20, 65%], P = 0.255), a finding which was in agreement with the report from the Surveillance, Epidemiology, and End Results Program, and also with other reports, 109, 110 with regard to an earlier peak of incidence of osteosarcoma among female individuals, consistent with an earlier growth spurt. Moreover, in line with previous reports, 21, 66, 104, 109, 110, 113 our study showed a nonsignificant trend toward a better OS in female individuals (HR = 0.4, 95% CI: 1.10-1.61, P = 0.197) compared with male individuals.
Knowing that our study neither included patients under 5 years of age, who are reported to have more aggressive disease, 114, 115 nor those whose age was older than 40 years, in whom there is almost a consensus in the literature that they have a worse survival, 21, 79, [116] [117] [118] survival in our study was steadily worse with increasing age, consistent with a study from the Netherlands that showed a statistically significant worse survival outcome in patients whose age was older than 20 years than in those whose age was 15 to 19 years, in whom outcomes were worse than those patients 14 years of age or below. 100 Intriguingly, their study showed a tendency of increase in the number of female individuals in younger age groups, as shown in our study. 102 A meta-analysis of prospective studies whose final cohort for analyses comprised 23 studies and 4403 patients from 5 international cooperative groups also showed that female individuals (P = 0.005) and children (P = 0.002) fared better than male individuals and adolescents or adults, respectively. 66 Our study showed no survival difference between preadolescent and adolescent patients in line with the findings of studies in which the age of 10 years was chosen as a proposed cutoff point. 80, 104, 105, 111 Moreover, compared with what was reported in some studies that osteosarcoma developed in the period of maximal growth rate had an inferior prognosis, 67,118 our study did not show a differential effect on prognosis (HR = 1.45, 95% CI: 0.30-7.02, P = 0.64) after applying the same age group subdivisions (13 to 15 y for boys and 12 to 14 y for girls), as was suggested in these studies as a period of the maximum growth rate. However, on the other side, applying a different age as a period of adolescence (male, age 13 to 17 y; female, age 12 to 16 y), as was suggested in another report from a meta-analysis, 66 a nonsignificant trend toward worse survival (HR = 2.5, 95% CI: 0.66-9.15, P = 0.18) was shown in adolescents compared with the nonadolescents, which may be due to a tendency toward more poor responders in the adolescent group (P = 0.156) ( Table 1) . Therefore, it would be difficult to define exactly a definite age range for maximal growth velocity in a single study due to various geographic, racial, socioeconomic, and also due to possible perturbed endogenous endocrine factors, or exogenous factors. [119] [120] [121] [122] [123] [124] Although a discernable hidden effect of response to chemotherapy on survival outcomes was observed in patients younger than 16 years of age (HR = 4.72, 95% CI: 3.73-7.23, P = 0.001) both in those patients 5-9 years of age, or those 10-14 years of age in our study, in line with what has been a long-standing known fact that a poor response to chemotherapy is a predictor of inferior outcome, 66, 69, 79, 111, 125, 126 however this large effect wasn't as such apparent in patients older than 16 years. 104 A relatively diminished differential effect of response to chemotherapy on survival in patients 16 years of age or above who, however, still have a worse survival outcome could be attributed to an inherent disease biology as well as with sex differences, due to potential differences in the way chemotherapy is handled by female individuals compared with male individuals and by children compared with older populations, consistent with previously published reports, 66, 102, 110, 127, 128 which indicated that age-dependent and sex-dependent pharmacologic differences in chemotherapy toxicity and efficacy may affect individual outcomes.
A statistically significant MFS difference was found at 5 years between patients 16 years of age or above and those younger than 16 years of age (37.5% vs. 84%, P = 0.01), although there was no difference between the 2 groups in the primary tumor response to chemotherapy (P = 0.44). In addition, the hazard for metastasis in patients 16 years of age or above (HR = 6.05, 95% CI: 1.43-25.6, P = 0.015) on survival compared with younger patients indicate that older age patients in our series had an inherent worse disease biology consistent with the of report the Japanese multiinstitutional study, 21 and with a recently published report showing that age-induced differentially expressed genes could be implicated as a potential molecular mechanism in osteosarcoma. 129 Although primary tumor size was not demonstrated to have independent effects on survival; however, hidden interaction effects with the tumor location within the limb could not be ruled out. Consistent with a previous report, which stated that the proportion of large tumors decreased with increasing distance from the trunk, 69 a larger proportion of patients with tumors located proximally within the limb (77.8%) (14/18) was found to have larger tumors ( > 5 cm) than those patients with tumors located distally (33.3% (4/12), P = 0.024). Moreover, tumors in the distal tibia 100% (3/3) were found to have a trend to be smaller in size ( ≤ 5 cm) than other sites (33.3% [9/27] , P = 0.054).
Moreover, an interaction effect between tumor location and response to chemotherapy was shown, wherein proximally located tumors within the limb were more likely to have poor response to chemotherapy (OR = 4.71, 95% CI: 0.94-23.7, P = 0.06), consistent with findings from a study. 130 Moreover, tumors located proximally within the limb in our study were found to have a higher propensity for systemic recurrences, wherein 4-year MFS in distal tumors was 88.9% versus 55% at 3 years in proximal tumors (P = 0.036). Variation of the regional blood flow in tumors arising in proximal locations was proposed by another study to contribute to systemic recurrences. 131 A larger sample is needed to delineate these complex interaction effects among these parameters, and whether response to chemotherapy could be affected by tumor size and/or the location of tumor within the limb. 130, 132 However, in the multivariable analysis, the location within the limb (HR = 2.62, 95% CI: 1.38-14.8, P = 0.002) gained a statistical significance to contribute independently to survival, comparable to findings from previous studies. 21, 69, 70, 126 In our series, 5-year LRFS was 100% in patients with a tumor in a distal metaphyseal site versus 77.8% at 2 years in a proximal one, P = 0.056. A worse 2-year LRFS was found to be associated with a proximal humeral site (50% vs. 95.8%, P = 0.007) versus other tumor sites. Local control failure in patients with tumors in a proximal metaphyseal site or particularly in a proximal humeral site could be explained on the basis of either technical difficulties related to obtaining adequate normal margins around the tumor, even if the resection margin was negative, or related to tumor chemoresistance with more propensity for local recurrence. 130, 131, 133, 134 Although poor response to chemotherapy was the most influential factor associated with more likelihood of limb amputation in the present study after controlling for the confounding factors (OR = 14.1, 95% CI: 1.34-149.4, P = 0.028), however, no difference was shown for either surgical approach on the survival in our study, albeit there was a nonstatistically significant trend to worse survival in patients who underwent limb amputation (HR = 1.59, 95% CI: 0.43-5.94, P = 0.49), as was shown in almost all published reports.
In line with what was reported from 2 recent metaanalyses of randomized control trials of surgical methods associated with osteosarcoma outcomes, 135, 136 and also with recently published reports from 2 small studies, 23, 24 all of which have indicated that dose-intensive multiagent chemotherapy regimens probably increase the rate of limb salvage surgery, we speculate that future intensification of therapy in our institute by incorporation of Ifosfamide or HDMTX may improve the rate of good responders via increasing dose-response relationship. Hence, a better local response would impact the orthopedic surgeon's decision to go safely for a limb salvage surgery.
However, in contrast, it will be unknown whether intensification of therapy in the future would be reflected as an advantage for survival by altering the course of aggressive disease through increasing the rate of good responders, wherein some previous reports showed that increase in the rate of good responders to dose-intensive chemotherapy has not been Table 5 , that is, "treatment period, location within the limb, and proximal humeral site" were saved and used as a "single covariate."
†The "single covariate" used to control for potential baseline confounders of the effect of "response to CTH" on "type of surgical procedure," that is, "covariate adjustment by propensity score."
‡Only the response to CTH that maintained its statistical significance in multivariable analysis. CI indicates confidence interval; CTH, chemotherapy; OR, odds ratio; Ref, reference; ROC, receiver operating characteristic.
paralleled with an improvement in survival outcomes 137, 138 ; hence, the debate was raised as to whether dose intensification is justified.
The main limitations are the sample size and the retrospective nature of the study; however, we made good use of the in-depth analysis of our study population to identify the details of patient characteristics, determine the factors of prognostic significance and points of weaknesses in treatment of patients, and thus to future insightful planning for life and limb saving, as well as for maintaining a better quality of life for children with osteosarcoma in a resourcelimited environment in Upper Egypt.
CONCLUSIONS
In Upper Egypt, despite the reasonable survival outcomes in nonmetastatic osteosarcoma, an encountered high amputation rate has clearly defined the trade-off between limb versus life in the setting of a country with limited resources. However, developing a model based on clinical patient characteristics for the prediction of surgical methods used in these patients is still feasible. Our results suggest that future planning to increase the rate of the good respondents by using multiagent dose-intensive chemotherapy regimens, in parallel with good supportive care, would enhance the rate of limb salvage surgery in our institute and may further improve the patients' survival.
